FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 百濟神州有限公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2025年5月12日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事 ...

截至5月12日收盘，创新药概念下跌0.60%，位居概念板块跌幅榜前列，板块内，迈威生物、百济神 州、泽璟制药等跌幅居前，股价上涨的有76只，涨幅居前的有通化金马、新开源、*ST赛隆等，分别上 涨6.84%、6.25%、5.01%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 中船系 | 6.55 | 重组蛋白 | -0.94 | | 成飞概念 | 5.77 | 代糖概念 | -0.82 | | 军工信息化 | 4.28 | 转基因 | -0.77 | | 同花顺果指数 | 4.17 | 创新药 | -0.60 | | 国产航母 | 3.73 | 粮食概念 | -0.60 | | 军民融合 | 3.69 | 玉米 | -0.59 | | 航空发动机 | 3.42 | 大豆 | -0.45 | | 人形机器人 | 3.20 | 农业种植 | -0.31 | | 减速器 | 3.20 | 生物质能发电 | -0.28 | | 军工 | 3.15 | 减肥药 | -0.24 | 资金面上看，今日创新药概念板块获主 ...

不过，需要注意的是，据观察者网，业内声音提到，总统行政令只能调控针对联邦政府医疗保险和医疗补助计划（政府 项目）的药价，无法直接强制药企降低对商业保险等支付方的价格。 智通财经记者 | 陈杨 智通财经编辑 | 谢欣 继今年4月美国总统特朗普宣布将对药品加征关税、并开启针对药品的"232条款调查"后，当地时间5月11日，其再次宣 布，将于当地时间5月12日签署行政令，使美国处方药和药品价格立刻下降30%至80%。其还将实施一项"最惠国政 策"，令美国支付与全球最低价国家相同的药价。 对此，特朗普给出的理由是，多年来美国处方药和药品价格比其他任何国家都高。而药企高额的研发投入没有理由只由 美国独自承担。他称，前述政策将使美国得到公平对待，最重要的是，美国将因此省下数万亿美元。 特朗普发言截图 相比之下，中国创新药市场仅占全球的3%。加上国内IPO融资受阻、支付天花板较低，出海尤其是进入美国市场成为国 内创新药公司的大趋势。海外大药企面对专利悬崖、新药开发难度攀升和全球激烈竞争，也需要国内优质资产补充管 线。 目前，仅有少数国内创新药公司产品已进入海外商业化阶段并实现在美国销售，包括百济神州的泽布替尼、替雷利珠单 ...

Investment Rating - The investment rating for the biopharmaceutical industry is "Positive" (maintained) [2] Core Insights - The report highlights the aggressive nature of small cell lung cancer (SCLC), with extensive stage SCLC accounting for approximately 75% of cases, which often rely on systemic treatment and have a poor prognosis [6][21] - The first-line treatment for extensive stage SCLC primarily involves PD-1/PD-L1 immunotherapy combined with doublet chemotherapy, while there are limited approved drugs for later-line treatments, indicating a significant unmet clinical need [24][30] - The report identifies three key areas of focus for research and development in the SCLC field: Antibody-Drug Conjugates (ADC), DLL3 T-cell engagers (TCE), and next-generation immune-oncology (IO) therapies [30][34] Summary by Sections 1. SCLC Overview - SCLC accounts for about 15%-20% of all lung cancer cases, with a high incidence of early metastasis [18][19] - The majority of SCLC cases are extensive stage, which has a poor prognosis and relies heavily on systemic therapies [21][22] 2. Treatment Landscape - The standard treatment for extensive stage SCLC has been established as a combination of chemotherapy and PD-1/PD-L1 immunotherapy, but the overall prognosis remains poor [24][25] - The NCCN and CSCO guidelines recommend various treatment options, including the recent inclusion of Tarlatamab as a preferred second-line treatment [28][29] 3. Research and Development Focus - ADCs are rapidly advancing in the SCLC field, targeting multiple hot spots such as B7-H3, DLL3, and TROP-2, with no ADC products currently approved for SCLC [37][38] - DLL3 TCEs, particularly Tarlatamab, have shown promising early data and are expected to reshape the treatment landscape for SCLC [30][31] - Next-generation IO therapies are being developed to challenge the current PD-L1 standard in first-line SCLC treatment [8][36] 4. Investment Recommendations - The report suggests that companies with strong pipelines in the SCLC space, such as Zai Lab, Zai Lab-U, Innovent Biologics, and others, are likely to benefit from the anticipated growth in the market as new data emerges [9]

Group 1 - The Hong Kong innovative drug sector continues to decline, with companies such as BeiGene and Galmed Pharmaceuticals dropping over 10% [1] - Innovent Biologics experienced a decline of over 7%, while other companies like Zai Lab and CSPC Pharmaceutical Group also saw significant drops [1]

Core Viewpoint - Public fund institutions remain highly active in conducting research on A-share companies, with a total of 146 institutions participating in 1,198 research instances during the week of May 5 to May 11, 2025, covering 156 stocks across 24 primary industries [1]. Group 1: Top Stocks in Research - The top ten stocks with the highest research frequency include: - LeiHan Intelligent (54 times, +3.41%) - BeiGene (49 times, -6.76%) - YiHe JiaYe (44 times, +10.70%) - DeMingLi (37 times, -3.14%) - XiangXin Technology (36 times, +5.32%) - AoHua Endoscopy (35 times, +4.30%) - WenJian Medical (35 times, -1.47%) - HongHua Digital Science (33 times, +8.77%) - XingYe YinXi (31 times, -1.73%) - ZhouDaSheng (29 times, +0.77%) [2]. Group 2: Industry Focus - The mechanical equipment industry stands out with LeiHan Intelligent leading in research frequency, attracting nearly 30% of public institutions [2]. - The pharmaceutical and biotechnology sector is also a major focus, with BeiGene and YiHe JiaYe ranking second and third in research frequency, respectively [3]. - The electronic, pharmaceutical, and mechanical equipment sectors are the primary areas of interest for public fund research, with a total of 538 research instances, accounting for 44.91% of all public fund research activities [3].

Market Overview - The market opened higher but retreated after reaching a peak, with the ChiNext Index leading the gains. The total trading volume in the Shanghai and Shenzhen markets reached 843.2 billion, an increase of 55.2 billion compared to the previous trading day. Over 3,400 stocks rose in the market [1] - The Shanghai Composite Index rose by 0.37%, the Shenzhen Component Index increased by 1.06%, and the ChiNext Index gained 1.72% [1] Sector Performance - The military industry stocks showed strong performance, with over 20 stocks hitting the daily limit, including Chengfei Integration and Tianjian Technology. The robotics sector also saw a resurgence, with stocks like Tuosida and Fenglong shares reaching the daily limit [1][3] - The ST (Special Treatment) stocks maintained their strength, with 30 stocks hitting the daily limit, including ST Qibu and ST Fanli [1][13] - Conversely, the pharmaceutical sector experienced a collective adjustment, with Baijie Shenzhou dropping nearly 10% [1] Individual Stock Highlights - A total of 32 stocks hit the daily limit in the morning session (excluding ST and newly listed stocks), with a sealing rate of 70%. Notable stocks include Chun Guang Technology with five consecutive limits, Chengfei Integration, and Lijun Shares with four consecutive limits [1] - Military stocks continued to show strength, with Chengfei Integration, Tianjian Technology, and Lijun Shares achieving four consecutive limits. Other notable stocks include Aerospace Nanhu and Huaru Technology, which also hit the daily limit [1][3] Industry Insights - The military industry is expected to see a rapid release of previously accumulated demand as 2025 approaches, which is the final year of the "14th Five-Year Plan." Some companies have already shown significant improvement in their fundamentals since February 2025, particularly in the aerospace and missile sectors [3] - The robotics sector is experiencing strong growth, with companies like Tuosida, Fenglong Shares, and Lijun Shares hitting the daily limit. The demand for humanoid robots is also increasing, as indicated by the positive developments in companies like Yushu Technology [7][19] International Relations Impact - Recent high-level economic talks between China and the U.S. held from May 10 to 11 in Geneva were described as candid, in-depth, and constructive, resulting in important consensus and substantial progress [13][22]

Core Viewpoint - The announcement of significant price reductions for prescription drugs in the U.S. has raised concerns among pharmaceutical companies, particularly those with innovative drugs approved in the U.S. market [1][3]. Group 1: Market Impact - The U.S. is the largest market for innovative drugs, benefiting from free pricing and patent laws, which allow high prices for these drugs [1]. - Following the announcement, shares of several Hong Kong-listed pharmaceutical companies with innovative drugs approved in the U.S. experienced notable declines, with BeiGene (百济神州) dropping over 7% and other companies like Hutchison China MediTech (和黄医药) and Junshi Biosciences (君实生物) also seeing significant drops [1]. Group 2: Company Performance - BeiGene has two self-developed drugs, BTK inhibitor Brukinsa (百悦泽) and PD-1 monoclonal antibody Tislelizumab (百泽安), both of which have been approved in the U.S. market, with Brukinsa contributing significantly to the company's revenue [3]. - In Q1, BeiGene reported revenue of 8.048 billion yuan, a 50.2% year-on-year increase, with Brukinsa's sales in the U.S. reaching 4.041 billion yuan, accounting for 50.2% of total revenue [3]. - The company transitioned from a loss to profitability, reporting a profit of approximately 150 million yuan and a GAAP net profit of $127,000 in the U.S. for the first time, attributed to rapid global revenue growth and effective cost management [3]. - BeiGene has set a revenue target for the year between 35.2 billion yuan and 38.1 billion yuan, with positive operating profit and cash flow expected [3]. Group 3: Future Considerations - Other pharmaceutical companies have indicated that the overall impact of the new pricing policy is still under evaluation [4].

Group 1 - The Hang Seng Index closed up 0.93%, while the Hang Seng Tech Index rose by 1.91% [1] - Apple-related stocks led the gains, with Sunny Optical Technology rising over 10% and AAC Technologies increasing by more than 9% [1] - The innovative drug sector experienced declines, with Genscript Biotech falling over 8% and BeiGene dropping more than 7% [1]

机构调研榜单中，共有161家公司获20家以上机构扎堆调研。兆威机电最受关注，参与调研的机构达到 332家；联影医疗被285家机构调研，榜单中排名第二；华勤技术、百济神州等分别被278家、251家机构 调研。 机构调研次数来看，曼卡龙机构调研最为密集，共获机构5次调研。雅戈尔、伟星股份等机构调研也较 为密集，分别被机构调研4次、3次。 数据宝统计，20家以上机构扎堆调研股中，近5日资金净流入的有57只，盛和资源近5日净流入资金2.59 亿元，主力资金净流入最多；净流入资金较多的还有焦点科技、祥鑫科技等，净流入资金分别为1.84亿 元、1.84亿元。 市场表现上，机构扎堆调研股中，近5日上涨的有118只，涨幅居前的有莱绅通灵、海能技术、欧陆通 等，涨幅为22.46%、17.16%、16.88%；下跌的有42只，跌幅居前的有容百科技、弘景光电、晶丰明源 等，跌幅为8.49%、8.29%、7.89%。（数据宝） 近5日机构调研股一览 | 证券代码 | 证券简称 | 机构调研次数 | 机构家数 | 最新收盘价（元） | 其间涨跌幅（%） | 行业 | | --- | --- | --- | --- | --- | -- ...